Table 1.
Pathogen and patient characteristics
| Characteristics | Total | MRSA | MSSA | P value |
|---|---|---|---|---|
| Patients | 104 | 60 | 44 | |
| Patient characteristics | ||||
| Female sex, n (%) | 41 (39.4) | 28 (46.7) | 13 (29.5) | 0.1044 |
| Age (months), median (IQRa) | 5.2 (49.6) | 3.9 (57.5) | 8.3 (49.4) | 0.424 |
| Age distribution | 0.7883 | |||
| ≤ 28 day | 31 (29.8) | 20 (33.3) | 11 (25.0) | |
| 29 day-3 years | 46 (44.2) | 25 (41.7) | 21 (47.7) | |
| 4–6 years | 10 (9.6) | 5 (8.3) | 5 (11.4) | |
| 7–15 years | 17 (16.4) | 10 (16.7) | 7 (15.9) | |
| Origin | 1.000 | |||
| Community associated | 57 (54.8) | 33 (55.0) | 24 (54.5) | |
| Hospital associated | 47 (45.2) | 27 (45.0) | 20 (45.5) | |
| Disease | 0.0031 | |||
| Skin and soft tissue infection | 37 (35.58) | 28 (46.7) | 9 (20.5) | |
| Pneumonia | 44 (42.3) | 24 (40.0) | 20 (45.5) | |
| Bloodstream infection | 21 (20.2) | 6 (10.0) | 15 (34.1) | |
| Bone and joint infection | 2 (1.9) | 2 (3.3) | 0 | |
| Laboratory examination | ||||
| White cell count-Median (IQR) (109/L) | 13.7 (9.88) | 13.9 (8.7) | 13.3 (12.4) | 0.5834 |
| Neutrophil count-Median (IQR) (109/L) | 7.9 (10.74) | 8.7 (10.4) | 7.2 (11.9) | 0.7365 |
| Neutrophils percentage-Median (IQR) | 61.6 (33.3) | 62.1 (30.0) | 60.9 (36.8) | 0.7107 |
| C-reactive protein-Median (IQR) (mg/L) | 18.5 (51.5) | 14.0 (66.0) | 24.0 (50.0) | 0.8506 |
| Co-infectionb | 34.0 (32.7) | 18.0 (30.0) | 16 (36.4) | 0.5308 |
| Hospitalization | ||||
| Hospital days-median (IQR) | 13 (11.0) | 12 (10) | 13 (10.8) | 0.9056 |
| Intensive care unit (ICU) admission | 26 (25.0) | 12 (20.0) | 14 (31.8) | 0.1789 |
| MLST | <0.0001 | |||
| 5 | 5 (4.8) | 0 | 5 (11.4) | |
| 6 | 5 (4.8) | 1 (1.7) | 4 (9.1) | |
| 7 | 4 (3.8) | 0 | 4 (9.1) | |
| 22 | 11 (10.6) | 2 (3.3) | 9 (20.5) | |
| 25 | 4 (3.8) | 0 | 5 (11.4) | |
| 59 | 49 (47.1) | 46 (76.7) | 3 (6.8) | |
| 188 | 4 (3.8) | 0 | 4 (9.1) | |
| 398 | 5 (4.8) | 0 | 5 (11.4) | |
| Othersc | 17 (16.3) | 11 (18.3) | 6 (13.6) | |
| spa type | <0.0001 | |||
| t002 | 4 (3.8) | 0 | 4 (9.1) | |
| t189 | 4 (3.8) | 0 | 4 (9.1) | |
| t309 | 12 (11.5) | 3 (5.0) | 9 (20.5) | |
| t437 | 41 (39.4) | 39 (65.0) | 2 (4.5) | |
| t441 | 4 (3.8) | 4 (6.7) | 0 | |
| t701 | 4 (3.8) | 0 | 4 (9.1) | |
| Othersd | 35 (33.7) | 14 (23.3) | 30 (68.2) | |
| SCCmec type (only for MRSA) | / | |||
| IV | 51 (85.0) | 51 (85.0) | / | |
| V | 6 (10.0) | 6 (10.0) | / | |
| NTe | 3 (5.0) | 3 (5.0) | / | |
aIQR, interquartile range
bIncluding bacteria (Pertussis, Acinetobacter baumanii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Mycobacterium Tuberculosis, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Enterobacter cloacae), fungus (Candida albicans, Candida krusei), virus (Respiratory syncytial virus, Influenza A virus, Adenovirus, Cytomegalovirus) and Mycoplasma pneumoniae
cThe other MLSTs were ST1 (1 isolate), ST30 (1 isolate), ST97 (1 isolate), ST121 (1 isolate), ST338 (2 isolates), ST896 (1 isolate), ST1224 (1 isolate), ST1821 (1 isolate) in the MRSA group, and ST1 (1 isolate), ST15 (3 isolates), ST121 (1 isolate), ST950 (1 isolate) in the MSSA group
dThe other spa types were t021 (1 isolate), t114 (3 isolates), t163 (1 isolate), t172 (2 isolates), t267 (1 isolate), t1751 (1 isolate), t3515 (1 isolate), t3590 (1 isolate), t4549 (1 isolate), t8860 (1 isolate), t12946 (1 isolate) in the MRSA group, and t034 (2 isolates), t078 (2 isolates), t084 (3 isolates), t091 (2 isolates), t127 (1 isolate), t163 (1 isolate), t167 (1 isolate), t310 (1 isolate), t571 (3 isolates), t660 (1 isolate), t796 (1 isolate), t1062 (1 isolate), t1818 (1 isolate), t2092 (1 isolate) in the MSSA group
eNontypable